Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.


BACKGROUND Survival outcomes for patients with osteosarcoma have remained stagnant over the past 30 years. Targeting of ganglioside GD2, a glycosphingolipid on the cell surface of some tumors, with immunotherapy has resulted in improved outcomes for patients with neuroblastoma. In the current study, the expression pattern of GD2 was examined in osteosarcoma… (More)
DOI: 10.1002/cncr.28461


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics